Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
1977 3
1978 8
1979 9
1980 5
1981 16
1982 20
1983 32
1984 26
1985 54
1986 71
1987 54
1988 59
1989 105
1990 98
1991 127
1992 104
1993 122
1994 130
1995 142
1996 176
1997 214
1998 277
1999 248
2000 358
2001 351
2002 449
2003 439
2004 472
2005 477
2006 529
2007 578
2008 597
2009 675
2010 736
2011 794
2012 781
2013 837
2014 867
2015 939
2016 979
2017 1043
2018 1039
2019 1147
2020 1343
2021 1565
2022 1430
2023 1463
2024 498

Text availability

Article attribute

Article type

Publication date

Search Results

20,332 results

Results by year

Filters applied: . Clear all
Page 1
Alzheimer's disease failed clinical trials.
Asher S, Priefer R. Asher S, et al. Life Sci. 2022 Oct 1;306:120861. doi: 10.1016/j.lfs.2022.120861. Epub 2022 Aug 4. Life Sci. 2022. PMID: 35932841 Review.
Lecanemab: First Approval.
Hoy SM. Hoy SM. Drugs. 2023 Mar;83(4):359-365. doi: 10.1007/s40265-023-01851-2. Drugs. 2023. PMID: 36856953 Review.
Masitinib for mild-to-moderate Alzheimer's disease: results from a randomized, placebo-controlled, phase 3, clinical trial.
Dubois B, López-Arrieta J, Lipschitz S, Doskas T, Spiru L, Moroz S, Venger O, Vermersch P, Moussy A, Mansfield CD, Hermine O, Tsolaki M; AB09004 Study Group Investigators. Dubois B, et al. Alzheimers Res Ther. 2023 Feb 28;15(1):39. doi: 10.1186/s13195-023-01169-x. Alzheimers Res Ther. 2023. PMID: 36849969 Free PMC article. Clinical Trial.
Senolytic therapy for Alzheimer's disease.
Longo FM, Massa SM. Longo FM, et al. Nat Med. 2023 Oct;29(10):2409-2411. doi: 10.1038/s41591-023-02541-y. Nat Med. 2023. PMID: 37758897 No abstract available.
Alzheimer's Disease: Advances in Drug Development.
Piton M, Hirtz C, Desmetz C, Milhau J, Lajoix AD, Bennys K, Lehmann S, Gabelle A. Piton M, et al. J Alzheimers Dis. 2018;65(1):3-13. doi: 10.3233/JAD-180145. J Alzheimers Dis. 2018. PMID: 30040716 Review.
Drug development for Alzheimer's disease: review.
Lao K, Ji N, Zhang X, Qiao W, Tang Z, Gou X. Lao K, et al. J Drug Target. 2019 Feb;27(2):164-173. doi: 10.1080/1061186X.2018.1474361. Epub 2018 Jun 20. J Drug Target. 2019. PMID: 29732929 Review.
20,332 results
You have reached the last available page of results. Please see the User Guide for more information.